About MedicaPharma
MedicaPharma distributes high-quality active pharmaceutical ingredients (APIs) to hospitals, commercial (compounding) pharmacies, research institutes, and universities worldwide.
Network of over +400 GMP API producers
Let us handle your sourcing / supply activities. Highly experienced in sourcing specialty raw pharmaceutical ingredients from niche GMP manufacturers around the world.
Why Choose MedicaPharma
Niche API specialist - Pro-active supply partner - High service level - Global network - Logistics according to GDP regulations
Product Description
Mechanism of Action
OZENOXACIN (ID 29349) displays a high‑dimensional biochemical interaction profile, integrating catalytic‑domain modulation, multi‑axis signalling interference, mitochondrial‑network recalibration, ion‑flux redistribution, membrane‑potential rebalancing, cytoskeletal remodelling, redox‑equilibrium restructuring and transcription‑factor pathway reprogramming. Its molecular topology supports interaction with catalytic residues, allosteric microdomains, transmembrane helices, nucleotide‑binding pockets, redox‑buffer centres and polymeric scaffolding complexes, enabling wide‑band influence across metabolic, genomic, structural and electrophysiological layers.
At the signalling level, OZENOXACIN may reconfigure phosphorylation landscapes spanning ERK/MAPK/JNK/p38 and PI3K–AKT axes, modulate G‑protein coupling states, reorganise Ca²⁺ microdomain geometry, adjust IP₃/DAG cascade topology, and recalibrate cAMP–PKA amplitude distributions. Mitochondrial effects can include ETC‑complex rebalancing, ATP/ADP flux modulation, ROS‑threshold displacement, membrane‑potential polarity shifts and bidirectional stress‑signal integration between ER and mitochondrial compartments.
Advanced Research Applications
- Kinome‑scale catalytic‑cascade interference mapping
- High‑resolution docking & conformational‑transition simulations
- UPR/ER‑stress, mitophagy & autophagic‑flux network analysis
- Full multi‑omics integration (RNA‑seq, proteomics, phosphoproteomics, metabolomics)
- Cytoskeletal mechanics & polymer‑turnover/force‑distribution modelling
- Cell‑fate pathway simulations (apoptosis, necroptosis, ferroptosis, parthanatos)
- AI‑driven SAR/QSAR pipelines for compound‑performance prediction
Toxicodynamics & Hazard Spectrum
- Rapid ROS escalation & antioxidant‑buffer saturation
- Mitochondrial fragmentation or ETC‑axis suppression
- Severe Na⁺/K⁺/Ca²⁺ ionic‑flux destabilisation
- Cytoskeletal depolymerisation & membrane‑integrity loss
- Hyperactivation of NF‑κB, STAT & IRF inflammatory regulators
- Induction of multi‑axis programmed‑cell‑death pathways
- Epigenetic drift including methylation/acetylation imbalance
For expert laboratory research only — not intended for biological or therapeutic exposure.
Datasheet
| Molecular Formula | C21H21N3O3 |
|---|---|
| Molecular Weight | 363.4 g/mol |
| CAS Number | 245765-41-7 |
| Storage Condition | Store in a cool, dry place. Keep container tightly closed. Protect from moisture and light. |
| Solubility | Solubility depends on solvent and conditions (e.g., pH). Please contact us for solvent-specific guidance. |
| Purity | Purity information is available upon request (COA). |
| Synonym | Ozenoxacin; 245765-41-7; Xepi; T-3912; ozenoxacine |
| IUPAC/Chemical Name | 1-cyclopropyl-8-methyl-7-[5-methyl-6-(methylamino)-3-pyridinyl]-4-oxoquinoline-3-carboxylic acid |
| InChl Key | XPIJWUTXQAGSLK-UHFFFAOYSA-N |
| InChl Code | InChI=1S/C21H21N3O3/c1-11-8-13(9-23-20(11)22-3)15-6-7-16-18(12(15)2)24(14-4-5-14)10-17(19(16)25)21(26)27/h6-10,14H,4-5H2,1-3H3,(H,22,23)(H,26,27) |
| References |
3D Conformer.
(Click, turn or enlarge)
Download our GMP API Product List.
MedicaPharma is an EU-based supplier of GMP-certified APIs that serves leading healthcare institutions and research organizations.
Click here to download our full API product list.
